• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy.人免疫缺陷病毒感染者亚临床冠状动脉疾病的蛋白质组学特征:REPRIEVE 机制子研究分析。
J Infect Dis. 2022 Nov 11;226(10):1809-1822. doi: 10.1093/infdis/jiac196.
2
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.在适合进行一级心血管预防的 HIV 成年患者中,使用计算机断层扫描血管造影术和炎症及免疫激活生物标志物评估冠心病。
JAMA Netw Open. 2021 Jun 1;4(6):e2114923. doi: 10.1001/jamanetworkopen.2021.14923.
3
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.匹伐他汀、前胶原途径与HIV患者的斑块稳定:REPRIEVE随机临床试验的二次分析
JAMA Cardiol. 2025 Mar 1;10(3):254-264. doi: 10.1001/jamacardio.2024.4115.
4
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort.在 REPRIEVE 队列中,HIV 感染者的冠状动脉旁脂肪组织密度、炎症与亚临床冠状动脉疾病。
Clin Infect Dis. 2023 Dec 15;77(12):1676-1686. doi: 10.1093/cid/ciad419.
5
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.吡咯烷二硫代氨基甲酸盐对 HIV 患者冠心病及炎症生物标志物的影响:REPRIEVE 随机临床试验的机制亚研究。
JAMA Cardiol. 2024 Apr 1;9(4):323-334. doi: 10.1001/jamacardio.2023.5661.
6
Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial.多基因风险评分与 HIV 感染者的临床前期心血管疾病:来自 REPRIEVE 试验的新认识。
J Am Heart Assoc. 2024 Apr 2;13(7):e033413. doi: 10.1161/JAHA.123.033413. Epub 2024 Mar 27.
7
Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV.无症状HIV初治人群中心肌肌钙蛋白T与冠状动脉粥样硬化的关联
JACC Adv. 2024 Aug 16;3(9):101206. doi: 10.1016/j.jacadv.2024.101206. eCollection 2024 Sep.
8
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States.美国人类免疫缺陷病毒感染者亚临床动脉粥样硬化和全身免疫激活/炎症的性别差异。
Clin Infect Dis. 2023 Jan 13;76(2):323-334. doi: 10.1093/cid/ciac767.
9
Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV.理想心血管健康、生物标志物与 HIV 感染者的冠状动脉疾病。
AIDS. 2023 Mar 1;37(3):423-434. doi: 10.1097/QAD.0000000000003418. Epub 2022 Nov 18.
10
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations.感染HIV者与未感染HIV的无症状社区人群及有症状的高风险人群的冠状动脉斑块情况
JACC Adv. 2024 May 3;3(6):100968. doi: 10.1016/j.jacadv.2024.100968. eCollection 2024 Jun.

引用本文的文献

1
Enhancing Cardiovascular Health in Southeastern United States for Underrepresented Racial and Ethnic Minorities With HIV: A Qualitative Inquiry Using the Health Belief Model.在美国东南部提高感染艾滋病毒的代表性不足的种族和族裔少数群体的心血管健康:一项基于健康信念模型的定性调查
J Assoc Nurses AIDS Care. 2025 Jul 29. doi: 10.1097/JNC.0000000000000576.
2
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.匹伐他汀、前胶原途径与HIV患者的斑块稳定:REPRIEVE随机临床试验的二次分析
JAMA Cardiol. 2025 Mar 1;10(3):254-264. doi: 10.1001/jamacardio.2024.4115.
3
The Primacy of Adipose Tissue Gene Expression and Plasma Lipidome in Cardiometabolic Disease in Persons With HIV.脂肪组织基因表达和血浆脂质组在HIV感染者心脏代谢疾病中的首要地位
J Infect Dis. 2025 Feb 20;231(2):e407-e418. doi: 10.1093/infdis/jiae532.
4
Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study.血浆蛋白质组学与 2 型糖尿病患者和非 2 型糖尿病患者冠心病发病的相关性:基于人群的 KORA 研究结果。
Cardiovasc Diabetol. 2024 Feb 3;23(1):53. doi: 10.1186/s12933-024-02143-z.
5
Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.艾滋病毒感染者中心血管疾病的发病机制和临床表现的演变:对治疗的影响。
Clin Microbiol Rev. 2024 Mar 14;37(1):e0009822. doi: 10.1128/cmr.00098-22. Epub 2024 Feb 1.
6
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus.血管内皮生长因子共受体神经纤毛蛋白-1在人类免疫缺陷病毒中的生物学及临床意义
Open Forum Infect Dis. 2023 Sep 8;10(10):ofad467. doi: 10.1093/ofid/ofad467. eCollection 2023 Oct.
7
High-throughput proteomic analysis reveals systemic dysregulation in virally suppressed people living with HIV.高通量蛋白质组学分析揭示了病毒抑制的 HIV 感染者的系统性失调。
JCI Insight. 2023 Jun 8;8(11):e166166. doi: 10.1172/jci.insight.166166.
8
Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV.靶向血浆蛋白质组学揭示了HIV感染者中不同炎症途径的上调。
iScience. 2022 Sep 7;25(10):105089. doi: 10.1016/j.isci.2022.105089. eCollection 2022 Oct 21.

本文引用的文献

1
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population.一般人群中亚临床冠状动脉粥样硬化的患病率。
Circulation. 2021 Sep 21;144(12):916-929. doi: 10.1161/CIRCULATIONAHA.121.055340. Epub 2021 Sep 20.
2
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention.在适合进行一级心血管预防的 HIV 成年患者中,使用计算机断层扫描血管造影术和炎症及免疫激活生物标志物评估冠心病。
JAMA Netw Open. 2021 Jun 1;4(6):e2114923. doi: 10.1001/jamanetworkopen.2021.14923.
3
Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells.慢性 HIV 感染诱导固有免疫细胞的转录和功能重编程。
JCI Insight. 2021 Apr 8;6(7):145928. doi: 10.1172/jci.insight.145928.
4
Molecular characterization of atherosclerosis in HIV positive persons.HIV 阳性者的动脉粥样硬化分子特征。
Sci Rep. 2021 Feb 5;11(1):3232. doi: 10.1038/s41598-021-82429-4.
5
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.慢性冠心病患者心血管死亡相关的血浆蛋白:一项回顾性研究。
PLoS Med. 2021 Jan 13;18(1):e1003513. doi: 10.1371/journal.pmed.1003513. eCollection 2021 Jan.
6
Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study.保留射血分数的心力衰竭合并症-炎症范式的蛋白质组学评估:来自 PROMIS-HFpEF 研究的结果。
Circulation. 2020 Nov 24;142(21):2029-2044. doi: 10.1161/CIRCULATIONAHA.120.045810. Epub 2020 Oct 9.
7
Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: A model for studying atherogenic mechanisms.HIV 感染者血液单核细胞来源的巨噬细胞成熟受到影响,并与血清脂质谱和激活指数相关:一种研究动脉粥样硬化机制的模型。
PLoS Pathog. 2020 Oct 1;16(10):e1008869. doi: 10.1371/journal.ppat.1008869. eCollection 2020 Oct.
8
Effects of NRP1 on angiogenesis and vascular maturity in endothelial cells are dependent on the expression of SEMA4D.NRP1 对血管内皮细胞血管生成和血管成熟的影响依赖于 SEMA4D 的表达。
Int J Mol Med. 2020 Oct;46(4):1321-1334. doi: 10.3892/ijmm.2020.4692. Epub 2020 Aug 3.
9
Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player.生长分化因子15在不良心脏重塑中的作用:从生物标志物到致病因素
ESC Heart Fail. 2020 Aug;7(4):1488-1501. doi: 10.1002/ehf2.12728. Epub 2020 May 18.
10
Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.利用蛋白质组学方法研究人类免疫缺陷病毒(HIV)感染和非 HIV 感染患者的差异血浆蛋白调节和他汀类药物作用。
J Infect Dis. 2020 Aug 17;222(6):929-939. doi: 10.1093/infdis/jiaa196.

人免疫缺陷病毒感染者亚临床冠状动脉疾病的蛋白质组学特征:REPRIEVE 机制子研究分析。

Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy.

机构信息

Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

Inova Heart and Vascular Institute, Falls Church, Virginia, USA.

出版信息

J Infect Dis. 2022 Nov 11;226(10):1809-1822. doi: 10.1093/infdis/jiac196.

DOI:10.1093/infdis/jiac196
PMID:35535576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10205625/
Abstract

BACKGROUND

People with HIV (PWH) have subclinical coronary artery disease (CAD) despite low traditional atherosclerotic cardiovascular disease (ASCVD) risk scores. Coronary plaque in PWH presents as a unique phenotype, but little is known about the contributions of specific inflammatory pathways to plaque phenotypes in PWH.

METHODS

The REPRIEVE Mechanistic Substudy enrolled PWH on ART without known cardiovascular disease. We used a targeted discovery proteomics approach to evaluate 246 unique proteins representing cardiovascular, inflammatory, and immune pathways. Proteomic signatures were determined for presence of coronary artery calcium (CAC > 0) and presence of coronary plaque.

RESULTS

Data were available for 662 participants (aged 51 [SD 6] years, ASCVD risk score 4.9% [SD 3.1%]). Among 12 proteins associated with both CAC and presence of coronary plaque, independent of ASCVD risk score, the odds ratios were highest for NRP1: 5.1 (95% confidence interval [CI], 2.3-11.4) for CAC and 2.9 (95% CI, 1.4-6.1) for presence of plaque. Proteins uniquely related to presence of plaque were CST3, LTBR, MEPE, PLC, SERPINA5, and TNFSF13B; in contrast, DCN, IL-6RA, OSMR, ST2, and VCAM1 were only related to CAC.

CONCLUSIONS

Distinct immune and inflammatory pathways are differentially associated with subclinical CAD phenotypes among PWH. This comprehensive set of targets should be further investigated to reduce atherosclerosis and ASCVD in PWH.

CLINICAL TRIALS REGISTRATION

NCT02344290.

摘要

背景

尽管艾滋病毒感染者(PWH)的传统动脉粥样硬化性心血管疾病(ASCVD)风险评分较低,但他们仍存在亚临床冠状动脉疾病(CAD)。PWH 的冠状动脉斑块表现为一种独特的表型,但对于特定炎症途径对 PWH 斑块表型的贡献知之甚少。

方法

REPRIEVE 机制子研究纳入了正在接受抗逆转录病毒疗法(ART)治疗且无已知心血管疾病的 PWH。我们使用靶向发现蛋白质组学方法来评估代表心血管、炎症和免疫途径的 246 种独特蛋白质。根据是否存在冠状动脉钙化(CAC > 0)和是否存在冠状动脉斑块来确定蛋白质组特征。

结果

共有 662 名参与者(年龄 51 [SD 6]岁,ASCVD 风险评分 4.9% [SD 3.1%])的数据可用。在与 CAC 和冠状动脉斑块均相关的 12 种蛋白中,NRP1 的比值比最高,与 CAC 相关的比值比为 5.1(95%置信区间 [CI],2.3-11.4),与斑块相关的比值比为 2.9(95% CI,1.4-6.1)。与斑块存在相关的蛋白为 NRP1、CST3、LTBR、MEPE、PLC、SERPINA5 和 TNFSF13B;相反,DCN、IL-6RA、OSMR、ST2 和 VCAM1 仅与 CAC 相关。

结论

在 PWH 中,不同的免疫和炎症途径与亚临床 CAD 表型存在差异相关。应该进一步研究这一全面的靶点集,以减少 PWH 的动脉粥样硬化和 ASCVD。

临床试验注册

NCT02344290。